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Abstract
Species of the Cannabis plant genus were among the earliest
medicinal plants cultivated by man, with historical accounts
of their medicinal uses dating back before the Common Era.
Despite its current legal status, Cannabis has garnered nationwide attention as a therapeutic agent for various disease
states, including chronic headaches, due to its medical indications as an antispastic, analgesic, antiemetic, neuroprotective
and anti-inflammatory agent Since headaches have a high
prevalence in the American population and greatly impair
simple daily aspects of living, chronic headaches have become a particular point of interest in regard to the therapeutic potential of Cannabis. Clinical trials and case reports have
shown that Cannabis administration for headaches has greatly improved the quality of life and decreased the use of adjuvant medications for some patients. Studies are limited and
conflicting, mostly due to the legal issues associated with
Cannabis. Pharmacists play a major role in managing patients who are treating their chronic headaches and need to
be able to educate patients about Cannabis. Patients may
consider trying to treat their headaches with Cannabis even
though it has legal restrictions regarding its use and is not
U.S. Food and Drug Administration (FDA) approved. Pharmacists should understand federal and state restrictions, drug
interactions, potential health risks, psychoactive effects and
types of delivery systems for Cannabis use.
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Introduction and Background
Species of the Cannabis plant genus (e.g., Cannabis sativa,
Cannabis indica) were among the earliest medicinal plants
cultivated by humans, with historical accounts of their
medicinal and entheogenic uses dating back before the Common Era, primarily in Ancient India and other Asiatic regions.1 In 1860, the Ohio State Medical Society organized the
first conference examining the clinical benefits of Cannabis
(also known as marijuana), and by 1870 the United States
Pharmacopoeia recognized Cannabis Americana in a separate monograph as a legitimate medical compound with analgesic, sedative and hypnotic potential. Despite revision of the
Cannabis monograph in 1880, the United States Pharmacopoeia removed Cannabis, USP in 1941, largely due to various
legal restrictions on its agricultural production. Although
efforts to elucidate the pharmacologic action and further
therapeutic potential of Cannabis were published in the
1950s and 1960s, Cannabis was eventually classified as a
schedule I substance under the Controlled Substances Act of
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1970, claiming Cannabis as a drug with no accepted medical
use and a high potential for abuse.
Despite its current legal status, Cannabis has garnered nationwide attention as a potential therapeutic agent Due to its
medical properties as an antispastic, analgesic, antiemetic,
neuroprotective and anti-inflammatory agent, it has demonstrated positive effects toward the therapy of various disease
states such as human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/ AIDS), various forms of cancer, multiple sclerosis (MS), chronic neuropathic pain,
Parkinson's disease, Tourette's syndrome and certain psychiatric diseases.2 Currently 20 states and the District of Columbia have enacted laws that allow medical Cannabis use with
the recommendation of a physician.3 Among the various disease states that Cannabis may treat, chronic headachesheadaches lasting more than 15 days a month for three
months or longer-have become a particular point of interest with respect to Cannabis therapy.4 This is primarily due
to the high prevalence of chronic headaches in the American
population and impairment of simple aspects of daily physical, social and occupational living. In the 21st century, efforts
to examine the therapeutic potential of Cannabis in chronic
headaches have largely focused on cannabinoids, the pharmacological compounds unique to both the Cannabis genus
and endogenous compounds in animal species.

Pharmacology and Medicinal Chemistry of Cannabinoids
The term cannabinoid describes the group ofterpenophenolic
compounds present both in Cannabis and in the nervous and
immune systems of a variety of animal species.5·6 Cannabinoids are further classified as (a) phytocannabinoids, those
which occur uniquely in the Cannabis plant; (b) endocannabinoids, those which are endogenously produced in animal
species; and (c) synthetic cannabinoids, those which are
chemically synthesized typically in a laboratory setting for the
purpose of additional pharmacological studies or eventual
marketing as a pharmaceutical preparation. At least 66 cannabinoids have been identified and isolated from the Cannabis plant, most of which differ in cyclization patterns from the
terpenophenolic precursor molecule cannabigerol (Figure 1).
Efforts to examine the pharmacologic activity and therapeutic potential of cannabinoids, though limited due to federal
legal restrictions, have largely focused on phytocannabinoids, particularly a 9-tetrahydrocannabinol (THC) and
(-)-cannabidiol (CBD) (Figure 1).7 Along with other cannabinoids, THC and CBD exert their pharmacologic effects on
the endogenous cannabinoid system, or endocannabinoid
system, located in human neural tissue and immune cells.
The receptors comprising the endocannabinoid system include the cannabinoid receptor type 1 (CB1 receptor) and the
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Figure 1. Cannabigerol, Tetrabydrocannabinol, Cannabidiol.
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cannabinoid receptor type 2 (CB2 receptor). Specifically,
CB1 receptors are densely located in neuron terminals of the
basal ganglia, cerebellum, hippocampus, neocortex, hypothalamus and limbic cortex, whereas CB2 receptors are located chiefly in immune cells. The extensive distribution of
CB1 receptors in the central nervous system renders the CB1
receptor an attractive target for potential treatment of the
neurological symptoms associated with chronic headaches.
Chronic headaches consist of a variety of disorders including
cluster headaches, hemicranias continua, idiopathic intracranial hypotension, migraines, tension type headaches and a
mixture of various types; however, the exact mechanism of
action of chronic headaches is not completely known, and the
onset of a chronic headache event may be completely unpredictable by the patients In the United States, 70 to 80 percent
of patients admitted to specialized headache clinics are diagnosed with chronic headaches and report a diminished quality of life due to impaired physical, social and occupational
function. Furthermore, over half of chronic headache patients report sleep disturbances, depression and anxiety,
which may worsen their symptoms.4 Research suggests that
the physical and neurological symptoms associated with
chronic headaches may stem from the inflammation of cranial nerves and blood vessels, changes in cranial blood vessel
sizes, cranial muscle tension and irregular changes in the
release of neurotransmitters (e.g., serotonin, norepinephrine,
dopamine} that regulate pain pathways.9
The principal psychoactive component in Cannabis, THC, has
demonstrated therapeutic potential to treat and manage mild
to moderate pain associated with chronic headaches, primarily due to its action as a partial agonist of the CB1 receptor.6-7
According to several small pharmacologic studies, the analgesic effects of THC may stem from its neuroprotective poFall 2014 Volume 6, Issue 1

tential. Specifically, THC has demonstrated an ability to modulate rostral ventromedial medulla (RVM} activity, disrupt
descending pain pathways and inhibit synthesis of prostaglandin, an endogenous regulator of inflammation associated
with chronic headaches.7 In neural tissue, the action of THC
on CB1 receptors reduces the contractile output and neurotransmitter release in smooth muscle, ultimately producing
characteristic analgesic effects.6 In contrast to the established therapeutic indications of THC, the pharmacologic activity of CBD, a nonpsychotropic component of Cannabis, is
not well understood, and there are conflicting views regarding the mechanism of CBD in the endocannabinoid system.1
Though CBD has no direct affinity for either the CB1or CB2
receptors, several studies have indicated that it may serve as
an allosteric antagonist on either cannabinoid receptor,
therein reducing the psychoactive effects of THC on CB1 and
CB2 receptors. 5 By reducing the affinity of THC for CB1 and
CB2 receptors, CBD may modulate the analgesic effects of
THC in neural and immune tissue. Although one of the primary medical delivery systems of phytocannabinoids in humans
is by smoking herbs of the Cannabis flower, THC and CBD can
also be administered by noncombustive vaporization of Cannabis herbs and oral ingestion of edible products containing
Cannabis-infused oils.7 Upon smoking, THC has an estimated
bioavailability of 10 to 25 percent, a distribution phase halflife of 0.5 hours and a terminal phase half-life of 30 hours,
primarily due to its extensive lipophilicity.On the other hand,
CBD has a similar lipophilic profile but a shorter terminal
phase half-life of nine hours. Following pulmonary administration, whether by combustive smoking or vaporization,
the analgesic effects useful to providing relief associated with
chronic headaches may occur as quickly as 30 seconds to
three minutes and typically last for two to three hours.s
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Current pharmacologic medications indicated for the treatment of chronic headaches include those that mimic
serotonin effects (e.g., triptans and dihydroergotamine-45),
modulate serotonin levels (e.g.. selective serotonin reuptake
inhibitors (SSRis)). reduce inflammation (e.g., antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDs) and
corticosteroids), stabilize blood vessels (e.g., calcium channel
blockers and beta blockers) and decrease muscle tension
(e.g.. muscle relaxants).9 Despite the historical success of
these medications as a maintenance therapy in relieving
symptoms associated with chronic headaches, these drugs
fail to provide the immediate relief that fits the almost instantaneous and unprecedented onset of a chronic headache
event. For example, some drugs, such as beta blockers and
SSRls, may take four to six weeks for any prolonged effect to
occur, and other analgesic drugs, such as NSAIDs and corticosteroids, may induce rebound headache events. Furthermore,
as single active pharmaceutical compounds, these drugs typically only target one of the many neuropathic features associated with chronic headaches, limiting the possibility of a
collective therapeutic approach to all symptoms. Cannabinoids, which provide a relatively fast onset of action, extensive half-life and pharmacologic potential to act on numerous
signaling pathways by way of CB1 receptors, serve as an attractive therapeutic option in treating chronic headaches.
Human Clinical Trials

Clinical data on Cannabis use among chronic headache patients is limited due to the fact that marijuana is classified as
a schedule I substance in the United States. 10 Therefore, its
use is strictly regulated and still illegal in many states; although some states have legalized the use of medicinal marijuana, it is still illegal on a national level. Another limiting
factor is that the exact pathophysiology of headaches is not
completely known, and it is likely that multiple different
mechanisms can produce headaches. Despite marijuana's
illegal status, some patients use it for relief of headache,
which is made easier by the increasing number of states that
are legalizing medical marijuana. There are no blinded studies on headache subjects from which true efficacy can be assessed. However, many observational case studies and case
reports have demonstrated resolution of headache symptoms with administration of Cannabis or dronabinol, the
pharmaceutical formulation of THC.
In 2012, Pini et al. published a randomized, double-blind,
active-controlled, crossover study regarding medication
overuse headache (MOH) in which they evaluated the efficacy and safety of nabilone (a synthetic THC analogue) in
reducing pain and frequency of headache.11 Medication overuse headache is a chronic headache lasting more than 15
days per month that develops from primary headaches
(migraine, tension-type headaches) as a result of overuse of a
pharmaceutical agent. The authors also evaluated quality of
life and analgesic intake in patients with MOH. Thirty MOH
patients were enrolled in a study at the University of
Modena's Interdepartmental Centre for Research on Headache and Drug Abuse (Italy}, which compared safety and efficacy between oral nabilone 0.5mg/day and oral ibuprofen
400mg/day. Patients were given eight weeks of nabilone fol-
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lowed by eight weeks of ibuprofen, or vice versa, with a one
week washout period between regimens. At the end of the
study, both treatments demonstrated improvements from
baseline, but nabilone showed greater efficacy in reducing
pain intensity, daily analgesic intake, and medication dependence. Adverse events due to nabilone were uncommon
and mild, and included dizziness, decreased appetite, vomiting, nausea, epigastric discomfort and dry mouth. Overall this
study demonstrated the potential benefit of nabilone in
relieving headache, decreasing analgesic consumption and
improving the quality of life while being relatively well tolerated. Due to the small sample size of this study, larger clinical
trials are needed to determine the clinical relevance of these
findings.
A case cohort report by Leroux et al. about the frequency of
Cannabis use in cluster headache patients reported the effects Cannabis had on the headache attacks.12 From July to
October 2009, 139 patients with cluster headaches answered
questionnaires in two French headache centers regarding
Cannabis use and its effects on cluster headaches. It was reported that 27 patients (19.4%) had tried Cannabis to treat
cluster headache attacks, of which 25.9 percent reported
some efficacy, 22.3 percent negative (worsening) effects and
51.8 percent variable or uncertain effects. The authors concluded that Cannabis use is relatively frequent in patients
with cluster headaches, but it has limited efficacy in treating
attacks due to the variable effects observed by patients. Multiple factors may have affected the data collected in the
study, such as the variations in amount of Cannabis inhaled
and possible differences in the cannabinoids produced in the
marijuana plants obtained by patients. Furthermore, the
study had a small sample size of 27 patients who had tried
Cannabis to treat their headaches, questioning if the power
of the study was sufficient to make adequate conclusions.
Additionally, collecting information by patient survey introduces many uncontrollable variables, and data that could
affect marijuana efficacy was not collected (patient current
medications, diet, exercise, genetics, etc.). The authors concluded that a recommendation for use of Cannabis to treat
cluster headaches is not justified unless further controlled
trials using synthetic cannabinoids demonstrate more
convincing evidence for efficacy. This study, although very
limited, shows that some patients are using marijuana to
self-treat their cluster headaches and that it is beneficial for
some patients.
An observational case study by Robbins et al. involved a
19-year-old male patient reporting to the Montefiore Headache Center (New York City) for management of his cluster
headaches.13 When untreated, the patient's headache attacks
occurred for about four hours every other day for a two week
period followed by a headache-free period of four to six weeks.
Prophylactic medications (verapamil, lithium, sodium valproate, melatonin, topiramate, nifedipine, indomethacin, zonisamide, venlafaxine, ergotamine tartrate and clonazepam) were
administered with either minimal success or intolerable adverse effects. Treatment for the patient's headaches with sumatriptan tablets, zolmitriptan nasal spray, ergotamine/
caffeine, oxycodone, aspirin/butalbital/caffeine, acetamino-
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phen/dichlorphenazone/isometheptene and indomethacin
were all ineffective as well However, the patient stated that
administration of marijuana by inhalation at the onset of the
headache consistently led to complete relief within five
minutes. Due to the lack of response to multiple other medications, the patient was given dronabinol Smg as a replacement
for marijuana for acute treatment of the headaches.
Dronabinol was found to consistently and dramatically relieve
the patient's cluster headaches within five to 15 minutes of
administration. The authors noted that the relief from headaches was probably not due to a placebo effect due to tl1e large
number of agents used that failed to prevent or treat the patient's headaches. However, other patients suffering from cluster headaches have reported that marijuana use can trigger
cluster headaches or worsen a current headache. This case
study shows that marijuana may have chemical components
that could be effective in the treatment of headaches, especially
those refractive to other medications, but it must be used with
caution because it has also been shown to trigger headache
attacks in some patients.
Role of the Pharmacist
Due to the prevalence of chronic headaches in the United
States and the growing interest in Cannabis as a viable medicinal agent, patients suffering from chronic headaches may
be interested in cannabinoids as agents for improving their
headaches. Important features of cannabinoids include the
ability of phytocannabinoids to be administered through rapidly-acting delivery systems, such as inhalation, and to provide a steady, collective relief from many of the neuropathic
features of chronic headaches. These benefits may lead patients to consider the use of cannabinoids as a replacement
to their current pharmacologic therapies. However, due to
the controversial legality of Cannabis, as well as its concerning psychoactive effects, many patients may consult health
care providers such as pharmacists for guidance. Pharmacists should have a good understanding of the potential benefits of cannabinoid treatment for chronic headaches as
demonstrated through clinical studies and case reports, and
they should also be mindful of federal and state restrictions
on Cannabis use. As Cannabis remains a schedule I substance
in the United States and has no federally-recognized accepted medical uses, it is important that the pharmacist not
actually recommend use of Cannabis, but rather explain that
several studies have demonstrated potential therape1Utic
benefits associated with the treatment of chronic headaches
for some patients. Not recommending these agents avoids
any legal consequences, but more importantly educates the
public that compounds in Cannabis may be beneficial to
treating treatment-resistant headaches and can greatly impact the quality of life of some patients. Some cannabinoids
may also be useful for treating chemotherapy-related nausea
and vomiting that has not been alleviated by conventional
treatments.

Additional counseling points about cannabinoids should include cautioning patients about the possible health risks.
These include lung or respiratory infections, chronic cough,
heart attack, psychosis and depression relating to certain
delivery systems for administering Cannabis (e.g., smoking);
Fall 2014 Volume 6, Issue 1
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potentially unwanted psychoactive effects that may lead to
cognitive impairment in daily social and occupational functioning, including hallucinations, paranoia, anhedonia, dizziness, driving impairment, decreased appetite, vomiting,
nausea and asthenia; and legal and occupational consequences associated with drug use in the workplace.14 Pharmacists
should also be aware of drug interactions of Cannabis or its
components in case patients admit that they are using Cannabis or are prescribed a cannabinoid. Major drug interactions include propoxyphene, buprenorphine, levomethadyl
acetate, sodium oxybate, alcohol and drugs causing central
nervous system depression.is
Conclusion
Many patients in the United States who suffer from chronic
headaches seek treatment because of the debilitating effects
of headaches in physical, social and occupational functioning.
Headache relief has been documented with administration of
Cannabis or its extracted ingredients in several case studies
and case reports; therefore Cannabis and its respective cannabinoids are worth studying despite strict and conflicting
legal restrictions in the United States. One major problem
with Cannabis use in the treatment of headaches is that
although activation of cannabinoid receptors may induce
pharmacologic effects that provide headache relief in some
patients, it may not provide relief in all patients, since the
mechanisms of chronic headaches are highly complex and
different among individual cases. Despite these challenges,
cannabinoids may still provide a more desired immediate
relief and an ability to treat multiple symptoms at once beyond the scope of conventional pharmaceutical treatments
that may only exhibit a limited number of pharmacologic
effects. Pharmacists play an important role in educating patients regarding the potential efficacy and safety of Cannabis
use in treating chronic headaches; however, additional studies are required to establish long-term safety and efficacy.
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